Abstract:A substantial amount patients with cancer will develop bone metastases, with 70% of metastatic prostate and breast cancer patients harboring bone metastasis. Despite advancements in systemic therapies for advanced cancer, survival remains poor for those with bone metastases. The interaction between bone cells and the immune system contributes to a better understanding of the role that the immune system plays in the bone metastasis of cancer. The immune and bone systems share various molecules, including transcription factors, signaling molecules, and membrane receptors, which can stimulate the differentiation and activation of bone‐resorbing osteoclasts. The process of cancer metastasis to bone, which deregulates bone turnover and results in bone loss and skeletal-related events (SREs), is also controlled by primary cancer-related factors that modulate the intratumoral microenvironment as well as cellular immune process. The nuclear factor kappa B ligand (RANKL) and the receptor activator of nuclear factor kappa B (RANK) are key regulators of osteoclast development, bone metabolism, lymph node development, and T-cell/dendritic cell communication. RANKL is an osteoclastogenic cytokine that links the bone and the immune system. In this review, we highlight the role of RANKL and RANK in the immune microenvironment and bone metastases and review data on the role of the regulatory mechanism of immunity in bone metastases, which could be verified through clinical efficacy of RANKL inhibitors for cancer patients with bone metastases. With the discovery of the specific role of RANK signaling in osteoclastogenesis, the humanized monoclonal antibody against RANKL, such as denosumab, was available to prevent bone loss, SREs, and bone metastases, providing a unique opportunity to target RANKL/RANK as a future strategy to prevent bone metastases.

Structure and Mechanism of OPG & RANK & RANKL and Their Effect on Bone Diseases

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Osteopontin in Bone Metabolism and Bone Diseases

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

RANKL and OPG Regulation on Bone Remodeling

Research Progress of RANK/RANKL/OPG Signaling Pathway

Research progress and application of OPG/RANK/RANKL signaling pathway in osteoporosis

Progress on OPG/RANKL/RANK System

Osteoblast–osteoclast interactions

Receptor Activator of Nuclear Factor-Κb Ligand (rankl)/rank/osteoprotegerin System in Bone and Other Tissues (Review)

A research comment about the mechanism of exercises influencing bone metabolism of OPG/RANKL/RANK system

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Rank/Osteoprotegerin System In Bone And Other Tissues

RANKL biology: bone metabolism, the immune system, and beyond

Osteopontin, a bridge links osteoarthritis and osteoporosis

The Role of RANKL in Bone Remodeling

RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling

Effects of Parathyroid Hormone on Osteoprotegerin Expression and Osteoprotegerin Ligand and Their Related Cytokines in Human Osteoblasts

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Discovery of the RANKL/RANK/OPG system

Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases